用双功能分子向蛋白质降解作为阿尔茨海默病及其他疾病的新疗法
C Alexander Sandhof1, Heide F B Murray1, M Catarina Silva1
1Department of Neurology, Precision Therapeutics Unit, Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
概括
向蛋白质降解 (TPD) 为治疗阿尔茨海默氏症 (AD) 和其他类型病变提供了一个有前途的新策略. 这种方法旨在降解有毒的蛋白,解决神经退行性疾病治疗中的一个关键挑战.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 和前性痴呆症 (FTD) 的特征是与蛋白质聚合相关的神经退行,特别是粉样质斑块和神经纤维状.
- 病理性积是病症的标志,有证据表明功能障碍导致疾病,如FTD中MAPT基因突变所示.
- 病理包括异常修饰,错误折叠,聚合和细胞间传播,但有效的疾病修饰疗法仍然有限.
研究的目的:
- 审查现有和潜在的向蛋白质降解 (TPD) 策略,以解决AD和FTD中的病理.
- 为了突出需要创新的治疗方式,由于当前病药物开发的挑战.
- 探索TPD的应用,以减少致病蛋白质的积累和聚合.
主要方法:
- 对实验性治疗方式的审查,重点是针对性蛋白质降解 (TPD) 策略.
- 在阿尔茨海默氏症和前性痴呆症的背景下,针对tau开发的TPD方法的分析.
- 探索其他可适应tau特定TPD的创新方法.
主要成果:
- 针对性蛋白质降解 (TPD) 策略显示,降解致病蛋白质具有显著的前景.
- TPD有可能减少病态蛋白质的积累和聚合.
- 目前的研究正在探索在神经退行性疾病中针对tau的各种TPD模式.
结论:
- 像TPD这样的创新治疗方式对于克服当前病治疗方法的局限性至关重要.
- TPD提供了一种新的机制来减少有毒陶的积累,这可能导致疾病的改变.
- 为了在AD和FTD中有效的特异性疗法,需要进一步开发和调整TPD策略.
相关概念视频
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Proteasome
813
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
813
Regulated Protein Degradation
2.5K
2.5K


